AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Advanced Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
Interventions
DRUG

Adavosertib

Given PO

Trial Locations (9)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

20007

MedStar Georgetown University Hospital, Washington D.C.

27710

Duke University Medical Center, Durham

32610

University of Florida Health Science Center - Gainesville, Gainesville

40536

University of Kentucky/Markey Cancer Center, Lexington

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado Hospital, Aurora

91010

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03253679 - AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification | Biotech Hunter | Biotech Hunter